Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13149815 | 0.84 | ALDH1A1 (0.53) | HRH3PROKR1 | |
| SCHEMBL4059188 | 0.84 | POLB (0.59) | PROKR1GFER | |
| SCHEMBL6179175 | 0.82 | PROKR1 (0.53) | PROKR1GFER | |
| SCHEMBL939096 | 0.82 | PROKR1 (0.63) | PROKR1GFER | |
| SCHEMBL937205 | 0.82 | PROKR1 (0.63) | PROKR1GFER | |
| SCHEMBL1859158 | 0.80 | PROKR1 (0.61) | PROKR1GFER | |
| SCHEMBL30667713 | 0.80 | PROKR1 (0.61) | PROKR1GFER | |
| SCHEMBL7496576 | 0.80 | SMN1; SMN2 (0.49) | PROKR1GFER | |
| SCHEMBL1857764 | 0.80 | HRH3 (0.65) | CHRNA7HRH3 | |
| SCHEMBL13503775 | 0.79 | HPGD (0.67) | CHRNA7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| EP-1761496-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005097751-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | HRH3, HRH4, HRH1 | CHRNA7 124/4885HRH3 1/4885CCNT1 4394/4885 |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | CHRNA7 451/4885HRH3 1/4885CCNT1 2799/4885 |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | CHRNA7 451/4885HRH3 1/4885CCNT1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.